RAPT THERAPEUTICS INC. - COMMON STOCK

RAPT Therapeutics Announces Positive Data, Including Objective Response Rates and Progression-Free Survival, from its Phase 2 Trial of FLX475 in Combination with a Checkpoint Inhibitor in Patients with Advanced NSCLC

03 Nov 2023 11:00:00 By Nasdaq GlobeNewswire

RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in November

01 Nov 2023 15:05:00 By Nasdaq GlobeNewswire

RAPT Therapeutics Announces Two FLX475 Presentations at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

18 Oct 2023 08:00:00 By Nasdaq GlobeNewswire

RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in September

30 Aug 2023 15:05:00 By Nasdaq GlobeNewswire

RAPT Therapeutics Reports Second Quarter 2023 Financial Results

11 Aug 2023 07:00:00 By Nasdaq GlobeNewswire

RAPT Therapeutics to Participate in the Goldman Sachs Global Healthcare Conference

07 Jun 2023 07:00:00 By Nasdaq GlobeNewswire

RAPT Therapeutics to Present Biomarker Data Corroborating Demonstrated Clinical Activity and Mechanism of Action of FLX475 in Advanced Cancers

25 May 2023 16:00:00 By Nasdaq GlobeNewswire

RAPT Therapeutics Reports First Quarter 2023 Financial Results

11 May 2023 07:00:02 By Nasdaq GlobeNewswire

RAPT Therapeutics Announces the Appointment of Michael Listgarten as General Counsel

03 May 2023 07:00:00 By Nasdaq GlobeNewswire

RAPT Therapeutics Announces FLX475 Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

26 Apr 2023 15:19:49 By Nasdaq GlobeNewswire

RAPT Therapeutics Announces Initiation of Phase 2a Trial of RPT193 in Patients with Moderate-to-Severe Asthma

29 Mar 2023 07:00:00 By Nasdaq GlobeNewswire

RAPT Therapeutics Reports Fourth Quarter And Year End Financial Results

14 Mar 2023 07:00:01 By Nasdaq GlobeNewswire

RAPT Therapeutics to Participate in the SVB Securities Global Biopharma Conference

07 Feb 2023 07:00:02 By Nasdaq GlobeNewswire

RAPT Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

03 Jan 2023 07:00:02 By Nasdaq GlobeNewswire

RAPT Therapeutics Presents Update from its Phase 1/2 Clinical Trial for FLX475 as Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Cancer

08 Dec 2022 05:30:00 By Nasdaq GlobeNewswire

RAPT Therapeutics to Present FLX475 Phase 1/2 Data at the European Society for Medical Oncology (ESMO) Immuno-Oncology Annual Congress

30 Nov 2022 18:05:22 By Nasdaq GlobeNewswire

RAPT Therapeutics Announces Pricing of Public Offering of Common Stock

17 Nov 2022 20:38:04 By Nasdaq GlobeNewswire

RAPT Therapeutics Announces Proposed Public Offering of Common Stock

17 Nov 2022 15:24:51 By Nasdaq GlobeNewswire

RAPT Therapeutics Reports Third Quarter 2022 Financial Results

10 Nov 2022 07:00:02 By Nasdaq GlobeNewswire

RAPT Therapeutics to Participate in Several Upcoming Investor Conferences

09 Nov 2022 07:00:01 By Nasdaq GlobeNewswire